## UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 24, 2020

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

## Zealand Pharma A/S

File No. 333-219184 - CF#33964

Zealand Pharma A/S submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form F-1 registration statement filed on July 6, 2017, as amended.

Based on representations by Zealand Pharma A/S that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:

Exhibit 10.1	through July 1, 2023
Exhibit 10.2	through July 1, 2023
Exhibit 10.3	through July 1, 2023
Exhibit 10.4	through July 1, 2023

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Patti J. Dennis Chief, Office of Disclosure Support